Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
52
CRL Quote, Financials, Valuation and Earnings
Last price:
$188.42
Seasonality move
:
6.25%
Day range:
$182.71 - $185.90
52-week range:
$91.86 - $202.72
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
2.30x
P/B ratio:
2.66x
Volume:
705.1K
Avg. volume:
1.1M
1-year change:
-3.77%
Market cap:
$9.1B
Revenue:
$4B
EPS (TTM):
-$1.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$990.8M | $2.34 | -1.55% | 75.74% | $189.27 |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.15% | 79.1% | $203.42 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.99% | 53.99% | $1,056.70 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -35.16% | -5.21% | $35.78 |
|
PODD
Insulet Corp.
|
$679M | $1.15 | 28.59% | 5.39% | $378.21 |
|
TECH
Bio-Techne Corp.
|
$291.3M | $0.42 | -2.32% | 99.75% | $69.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$184.31 | $189.27 | $9.1B | 913.13x | $0.00 | 0% | 2.30x |
|
JNJ
Johnson & Johnson
|
$201.93 | $203.42 | $486.5B | 19.49x | $1.30 | 2.55% | 5.31x |
|
LLY
Eli Lilly & Co.
|
$1,010.31 | $1,056.70 | $904.2B | 49.97x | $1.50 | 0.59% | 15.50x |
|
MRNA
Moderna, Inc.
|
$27.70 | $35.78 | $10.8B | -- | $0.00 | 0% | 4.81x |
|
PODD
Insulet Corp.
|
$304.49 | $378.21 | $21.4B | 88.35x | $0.00 | 0% | 8.74x |
|
TECH
Bio-Techne Corp.
|
$61.68 | $69.17 | $9.6B | 126.08x | $0.08 | 0.52% | 7.99x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
43.59% | 1.998 | 33.97% | 0.85x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
PODD
Insulet Corp.
|
42.7% | 1.380 | 4.75% | 1.89x |
|
TECH
Bio-Techne Corp.
|
16.71% | 1.206 | 4.55% | 2.31x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International, Inc.
|
$324.7M | $151.1M | -1.27% | -2.28% | 15.04% | $178.2M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
PODD
Insulet Corp.
|
$513.5M | $117.7M | 9.14% | 18.92% | 16.66% | $94.6M |
|
TECH
Bio-Techne Corp.
|
$190.2M | $50.8M | 3.2% | 3.85% | 17.72% | $22.2M |
Charles River Laboratories International, Inc. vs. Competitors
-
Which has Higher Returns CRL or JNJ?
Johnson & Johnson has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 21.47%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About CRL or JNJ?
Charles River Laboratories International, Inc. has a consensus price target of $189.27, signalling upside risk potential of 2.69%. On the other hand Johnson & Johnson has an analysts' consensus of $203.42 which suggests that it could grow by 0.74%. Given that Charles River Laboratories International, Inc. has higher upside potential than Johnson & Johnson, analysts believe Charles River Laboratories International, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.9 8 0 JNJJohnson & Johnson9 11 0 -
Is CRL or JNJ More Risky?
Charles River Laboratories International, Inc. has a beta of 1.633, which suggesting that the stock is 63.257% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock CRL or JNJ?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.55% to investors and pays a quarterly dividend of $1.30 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or JNJ?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Johnson & Johnson's PE ratio is 19.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.30x versus 5.31x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.30x 913.13x $1B $55.6M JNJJohnson & Johnson5.31x 19.49x $24B $5.2B
-
Which has Higher Returns CRL or LLY?
Eli Lilly & Co. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 31.72%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About CRL or LLY?
Charles River Laboratories International, Inc. has a consensus price target of $189.27, signalling upside risk potential of 2.69%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Eli Lilly & Co. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Eli Lilly & Co. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.9 8 0 LLYEli Lilly & Co.17 8 0 -
Is CRL or LLY More Risky?
Charles River Laboratories International, Inc. has a beta of 1.633, which suggesting that the stock is 63.257% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock CRL or LLY?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or LLY?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.30x versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.30x 913.13x $1B $55.6M LLYEli Lilly & Co.15.50x 49.97x $17.6B $5.6B
-
Which has Higher Returns CRL or MRNA?
Moderna, Inc. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of -19.69%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About CRL or MRNA?
Charles River Laboratories International, Inc. has a consensus price target of $189.27, signalling upside risk potential of 2.69%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 29.16%. Given that Moderna, Inc. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Moderna, Inc. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.9 8 0 MRNAModerna, Inc.4 15 1 -
Is CRL or MRNA More Risky?
Charles River Laboratories International, Inc. has a beta of 1.633, which suggesting that the stock is 63.257% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock CRL or MRNA?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or MRNA?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are smaller than Moderna, Inc. quarterly revenues of $1B. Charles River Laboratories International, Inc.'s net income of $55.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.30x versus 4.81x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.30x 913.13x $1B $55.6M MRNAModerna, Inc.4.81x -- $1B -$200M
-
Which has Higher Returns CRL or PODD?
Insulet Corp. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 12.4%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Insulet Corp.'s return on equity of 18.92%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B PODDInsulet Corp.72.7% $1.24 $2.4B -
What do Analysts Say About CRL or PODD?
Charles River Laboratories International, Inc. has a consensus price target of $189.27, signalling upside risk potential of 2.69%. On the other hand Insulet Corp. has an analysts' consensus of $378.21 which suggests that it could grow by 24.21%. Given that Insulet Corp. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Insulet Corp. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.9 8 0 PODDInsulet Corp.18 2 0 -
Is CRL or PODD More Risky?
Charles River Laboratories International, Inc. has a beta of 1.633, which suggesting that the stock is 63.257% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.
-
Which is a Better Dividend Stock CRL or PODD?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or PODD?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are larger than Insulet Corp. quarterly revenues of $706.3M. Charles River Laboratories International, Inc.'s net income of $55.6M is lower than Insulet Corp.'s net income of $87.6M. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Insulet Corp.'s PE ratio is 88.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.30x versus 8.74x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.30x 913.13x $1B $55.6M PODDInsulet Corp.8.74x 88.35x $706.3M $87.6M
-
Which has Higher Returns CRL or TECH?
Bio-Techne Corp. has a net margin of 5.53% compared to Charles River Laboratories International, Inc.'s net margin of 13.32%. Charles River Laboratories International, Inc.'s return on equity of -2.28% beat Bio-Techne Corp.'s return on equity of 3.85%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International, Inc.32.32% $1.10 $6.1B TECHBio-Techne Corp.66.37% $0.24 $2.4B -
What do Analysts Say About CRL or TECH?
Charles River Laboratories International, Inc. has a consensus price target of $189.27, signalling upside risk potential of 2.69%. On the other hand Bio-Techne Corp. has an analysts' consensus of $69.17 which suggests that it could grow by 12.14%. Given that Bio-Techne Corp. has higher upside potential than Charles River Laboratories International, Inc., analysts believe Bio-Techne Corp. is more attractive than Charles River Laboratories International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International, Inc.9 8 0 TECHBio-Techne Corp.11 3 0 -
Is CRL or TECH More Risky?
Charles River Laboratories International, Inc. has a beta of 1.633, which suggesting that the stock is 63.257% more volatile than S&P 500. In comparison Bio-Techne Corp. has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.414%.
-
Which is a Better Dividend Stock CRL or TECH?
Charles River Laboratories International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Techne Corp. offers a yield of 0.52% to investors and pays a quarterly dividend of $0.08 per share. Charles River Laboratories International, Inc. pays -- of its earnings as a dividend. Bio-Techne Corp. pays out 69.67% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or TECH?
Charles River Laboratories International, Inc. quarterly revenues are $1B, which are larger than Bio-Techne Corp. quarterly revenues of $286.6M. Charles River Laboratories International, Inc.'s net income of $55.6M is higher than Bio-Techne Corp.'s net income of $38.2M. Notably, Charles River Laboratories International, Inc.'s price-to-earnings ratio is 913.13x while Bio-Techne Corp.'s PE ratio is 126.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International, Inc. is 2.30x versus 7.99x for Bio-Techne Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International, Inc.2.30x 913.13x $1B $55.6M TECHBio-Techne Corp.7.99x 126.08x $286.6M $38.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.44% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.33% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.85% over the past day.
